Answers are grounded in this paper and cite their sources.
Breast cancer is the most prevalent malignancy among women worldwide. Increasing evidence implicates human papillomavirus (HPV) in breast cancer, particularly HPV16 and HPV18. However, the underlying mechanisms remain unclear. This study investigated the role of the TGF-β/ID1 signaling axis in HPV16/18 E6/E7 mediated malignant transformation of mammary epithelial cells. Stable MCF-10A cell lines expressing E6/E7 were established. E6/E7 expression promoted malignant transformation of mammary epithelial cells. RNA sequencing revealed extensive transcriptional reprogramming, with enrichment of cell cycle and DNA replication pathways. Gene set enrichment analysis and flow cytometry confirmed accelerated cell cycle progression, with increased S and G2/M phase populations. Mechanistically, E6/E7 upregulated TGFB2 and enhanced SMAD3 phosphorylation, indicating activation of canonical TGF-β signaling. TGFB2 silencing reduced SMAD3 activation and suppressed proliferation. E6/E7 also induced the downstream target ID1, whereas TGFB2 knockdown decreased ID1 expression. ID1 depletion inhibited proliferation and induced cell cycle arrest. In summary, E6/E7 promotes cell cycle progression and tumor initiating capacity via activation of the TGFB2–TGF-β–ID1 axis, providing mechanistic insight into HPV associated breast malignant transformation.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: